NORD remembers actor Jack Klugman for support to the Orphan Drug Act

NewsGuard 100/100 Score

Jack Klugman touched the lives of millions of Americans through his support for what ultimately became the Orphan Drug Act.  By portraying on his Quincy, M.E. television show the plight of people with rare diseases with no treatment, Mr. Klugman focused a spotlight on the need for incentives to encourage the development of therapies for small patient populations.  He did this in partnership with patients and patient advocates who had been unable to gain national attention until he lent his support. 

In 1993, Mr. Klugman told a Chicago Tribune interviewer that his interest in the Quincy TV show stemmed partly from the fact that it allowed him to do important shows on important topics – not just to entertain.  By airing two episodes on the need for treatments for people with rare diseases, he addressed a very important public health challenge.

Mr. Klugman's death comes just one week before the start of the 30th anniversary year of the Orphan Drug Act of 1983 and the establishment of NORD to represent rare disease patients and patient organizations.  NORD will always remember him as one of the best friends the rare disease community has ever had.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global end-to-end solutions partner to life sciences organisations, AscellaHealth, joins Manchester Science Park